• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued?

    Simply Wall St·07/15/2026 19:35:06
    语音播报

    Agios Pharmaceuticals (AGIO) is back in focus after the U.S. Food and Drug Administration accepted its supplemental New Drug Application for mitapivat in sickle cell disease under Priority Review, using the accelerated approval pathway.

    See our latest analysis for Agios Pharmaceuticals.

    At a share price of US$39.92, Agios Pharmaceuticals has had a 30 day share price return of 35.51% and a year to date share price return of 46.87%. The 1 year total shareholder return of 1.86% suggests momentum has been more concentrated in recent months than over the longer term.

    If this FDA decision has you looking across healthcare, it could be a useful moment to see what else is moving among 40 healthcare AI stocks.

    After a sharp move higher on the FDA news, Agios Pharmaceuticals now sits closer to analyst targets but still trades at a steep modelled discount, raising the question of whether most of the rerating is done or whether valuation could support further upside.

    Most Popular Narrative: 2.3% Undervalued

    Agios Pharmaceuticals last closed at $39.92 against a most followed narrative fair value of $40.88, putting a modest valuation gap in clear focus.

    Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios' addressable market, driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which should lift revenue growth in coming years.

    Read the complete narrative. Read the complete narrative.

    The core story behind that $40.88 fair value hinges on expectations of rapid revenue scaling, a sharp margin shift, and a future earnings multiple that is usually reserved for much larger biotechs. Curious which assumptions would have to align to support that view?

    Result: Fair Value of $40.88 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the heavy reliance on PYRUKYND and ongoing high R&D and SG&A spending mean any clinical or regulatory setback could quickly challenge this Agios Pharmaceuticals narrative.

    Find out about the key risks to this Agios Pharmaceuticals narrative.

    Another View: Agios Pharmaceuticals Through a Sales Multiple Lens

    While the most followed Agios Pharmaceuticals narrative leans on future cash flows, the current price tells a very different story when compared with sales. The stock trades on a P/S of 35.9x versus 11.2x for the wider US biotech industry and 3.1x for peers, with a fair ratio estimate of 0x suggesting the market could move toward a much lower sales multiple over time. For an investor, that gap points to meaningful valuation risk if sentiment or growth expectations cool, so how comfortable are you with paying such a premium for today’s revenue base?

    To pressure test those sales based signals against a fuller valuation breakdown, it can help to step through the detailed multiples workup and see how each assumption stacks up against both the industry and peers, as well as the fair ratio our models point to, before deciding how much premium feels acceptable. See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:AGIO P/S Ratio as at Jul 2026
    NasdaqGS:AGIO P/S Ratio as at Jul 2026

    Next Steps

    With sentiment on Agios Pharmaceuticals split between caution and optimism, this is a moment to move quickly, unpack the data, and weigh both the potential risks and rewards for yourself using the 2 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Agios Pharmaceuticals?

    Do not stop with Agios Pharmaceuticals when there are other potential opportunities on your radar. Use the Simply Wall St screener to quickly surface ideas that fit your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.